Introduction
============

Primary open angle glaucoma (POAG) is the most common subtype of glaucoma, which can be regarded as a group of diseases with characteristic optic neuropathy that causes a distinctive pattern of progressive visual field loss that could eventually lead to blindness \[[@r1]\]. Several genes known to cause POAG have been identified, such as myocilin (*MYOC*),  optineurin (*OPTN*), WD repeat domain 36 (*WDR36*), and neurotrophin 4 (*NTF4*), though the exact mechanisms by which they are causal remains unclear \[[@r2]-[@r5]\]. Conflicting evidence for association has created uncertainty about the importance of *OPTN* and *NTF4* in POAG \[[@r6],[@r7]\] in the general population, though there is evidence that *OPTN* may be specific for normal tension glaucoma (NTG) \[[@r3]\]. These genes are rare causes of the disease, and are detected in families affected by glaucoma, and thus account for few (\<10%) POAG cases in total \[[@r8]\]. Association studies detect more common causes of disease and, more recently, several replicated genes have been detected using this method either on a genome-wide scale or by candidate gene analysis. Examples are a variant near the caveolin 1 (*CAV1*) and caveolin 2 (*CAV2*) genes on chromosome 7 \[[@r9],[@r10]\]; transmembrane and coiled-coil domains 1 (*TMCO1*) and CDKN2B antisense RNA 1 (*CDKN2B-AS1*) \[11\], ELOVL fatty acid elongase 5 (*ELOVL5*), S1 RNA binding domain 1 (*SRBD1*) \[[@r12]\].

There have also been recent successes in identifying genes associated with quantitative ocular traits important in POAG such as intraocular pressure (IOP), vertical cup disc ratio (CDR), optic disc area, and central corneal thickness (CCT). Genes known to be involved with these traits include atonal homolog 7 (*ATOH7*), transforming growth factor, beta receptor III (*TGFBR3*), SIX homeobox 1 (*SIX1*), and caspase recruitment domain family, member 10 (*CARD10*) with optic disc size and vertical cup disc ratio \[[@r13]-[@r15]\], as well as zinc finger protein 469 (*ZNF469*), A kinase (PRKA) anchor protein 13 (*AKAP13*), and collagen, type V, alpha 1 (*COL5A1*) with CCT \[[@r16]-[@r18]\].

Genome-wide association studies (GWAS) have been performed in a wide range of complex diseases, including diabetes, age-related macular degeneration, Crohn's disease and bipolar disorder \[[@r19],[@r20]\]. Many common variants have been reproducibly associated with these and many other common diseases. GWAS has therefore been the principal strategy employed, over the last few years, to uncover the genetics of complex traits. We performed a GWAS of risk in 387 POAG patients and 5,830 Wellcome trust case controls consortium (WTCCC2) controls and assessed genetic correlation with quantitative ocular traits in these 387 cases and 50 Southampton controls. We then followed up promising single nucleotide polymorphisms (SNPs) in a further 294 POAG patients.

Methods
=======

Patient samples and phenotypes
------------------------------

Three hundred and eighty seven (387) primary open angle patients from a cohort of patients being recruited in Hampshire (UK) were included in this study. Patients were recruited following the tenets of the declaration of Helsinki, informed consent was obtained and the research was approved by the Southampton & South West Hampshire Research Ethics Committee. Patients were all diagnosed as POAG cases and further defined as normal tension glaucoma (NTG) if the average IOP over both eyes ≤21 mmHg, and high tension glaucoma (HTG) if otherwise. All showed visual field loss in at least one eye. A full description of the cohort is given elsewhere \[[@r21]\]. Cases diagnosed as psuedoexfoliation glaucoma and those with a known myocilin mutation were excluded. The replication sample consisted of 294 further POAG cases collected from Southampton, Portsmouth and additional sites on this study in Frimley, Torbay, and Wolverhampton. Myocilin positive cases could not be excluded due to incomplete screening. Descriptions of both the discovery and replication sample are given in [Table 1](#t1){ref-type="table"}.

###### Demographic information on patients and controls of POAG discovery and replication samples.

  ** Descriptive**     **Discovery sample POAG cases**   **Replication sample POAG cases**   **p-value differences between discovery and replication samples**   **WTCCC2 controls**   **Southampton controls**
  -------------------- --------------------------------- ----------------------------------- ------------------------------------------------------------------- --------------------- --------------------------
  No. of subjects      n=387                             n=294                                                                                                   n=5380                n=50
  **Diagnosis**                                                                                                                                                                        
  POAG                 387                               294                                                                                                     NA                    0 (0%)
  HTG                  319(82%)                          233(79%)                                                                                                NA                    0 (0%)
  NTG                  68(18%)                           61(21%)                             p=0.3†                                                              NA                    0 (0%)
  **Age in years**                                                                                                                                                                     
  Mean                 75.3                              73.1                                                                                                    NA                    79
  Standard deviation   10.6                              10.7                                p=0.0077\*                                                          NA                    4.9
  **Gender**                                                                                                                                                                           
  Female               193                               144                                                                                                     2647                  27
  Male                 194                               150                                 p=0.82†                                                             2733                  23

This table describes the diagnosis, age and gender of the discovery and replication POAG case and control samples. POAG=primary open-angle glaucoma; HTG=high tension glaucoma, NTG=normal tension glaucoma; p-value \*significance of independent samples T- test, †significance of 2×2 χ^2^ test; NA=not available. WTCCC2=Wellcome Trust Case Control Consortium 2 controls --including 1958 British birth cohort and national blood service cohort members. Southampton Controls --have no sign of Glaucoma or Age-related macular degeneration.

The quantitative ocular traits analyzed were; intraocular pressure (IOP) taken as the maximum observed and average value per patient (measured by Goldman applanation tonometry), cup:disc ratio taken as the worst eye and average per patient, and central corneal thickness (CCT) taken as average over both eyes (measured by ultrasound pachymetry- Tomey pachymeter SP-3000; Tomey USA, Phoenix, AZ). Although data were mostly complete for IOP and CDR, fewer data were available for CCT. These ocular traits were also measured in the 50 Southampton controls. Details are given in [Table 2](#t2){ref-type="table"}.

###### Quantitative trait phenotypes for patients and controls of POAG discovery and replication samples.

                                                               **Discovery sample POAG cases (n=387)**   **Replication sample POAG cases (n=294)**   **Southampton control sample (n=50)**                                 
  ------------------------------------------------------------ ----------------------------------------- ------------------------------------------- --------------------------------------- ------------- --------------- -------------
  **Descriptive**                                              **worst eye**                             **average**                                 **worst eye**                           **average**   **worst eye**   **average**
  **Highest observed intraocular pressure (IOP)**                                                                                                                                                                          
  Mean                                                         27.75                                     25.90                                       26.7                                    24.9          15.74           15.53
  SD                                                           6.38                                      5.44                                        7.04                                    5.8           3.02            3.00
  Minimum                                                      14                                        14                                          13                                      12.5          10              10
  Maximum                                                      60                                        54                                          58                                      43            21              21
  N                                                            387                                       387                                         282                                     282           50              50
  Missing data                                                 0                                         0                                           12                                      12            0               0
  **Cup:disc ratio (CDR)**                                                                                                                                                                                                 
  Mean                                                         0.78                                      0.72                                        0.76                                    0.71          0.32            0.30
  SD                                                           0.14                                      0.15                                        0.16                                    0.15          0.13            0.12
  Minimum                                                      0.08                                      0.08                                        0                                       1             0.1             0.1
  Maximum                                                      1                                         1                                           1                                       0.975         0.7             0.6
  N                                                            387                                       387                                         283                                     283           49              49
  Missing data                                                 0                                         0                                           11                                      11            1               1
  **Central corneal thickness (CCT) average over both eyes**                                                                                                                                                               
  Mean                                                         534                                       539                                         552                                                                   
  SD                                                           34.19                                     40.5                                        34.5                                                                  
  Minimum                                                      417                                       398                                         439                                                                   
  Maximum                                                      624                                       639                                         620                                                                   
  N                                                            191                                       201                                         48                                                                    
  Missing data                                                 196                                       93                                          2                                                                     

This table gives statistical descriptions of the quantitative ocular traits measured in the discovery and replication POAG cases and the replication controls. No phenotypic information is available for the discovery WTCCC2 controls.

Genotyping and QC
-----------------

The discovery sample was genotyped using the Affymetrix SNP 6.0 array (Affymetrix, Santa Clara, CA) and frequencies were compared with the Affymetrix SNP 6.0 array data available for approximately 5,000 WTCCC2 controls, originating from the National Blood Service and the 1948 British birth cohort. The replication sample genotyping was performed using [KASPar](http://www.kbioscience.co.uk/reagents/KASP/KASP.html) chemistry.

Quality control steps involved removing cases and SNPs with a high degree of missingness, and removing SNPs with a minor allele frequency less than 5%. We also performed identity by state (IBS) analysis to identify unknown relatives or duplicates and multi-dimensional scaling (MDS) to identify those with differing ethnic backgrounds to the majority of the group (a Caucasian cohort). The WTCCC2 controls clustered tightly together with our cases in the MDS plot, showing that our cases and controls were ethnically compatible ([Appendix 1](http://www.molvis.org/molvis/v18/a115/app-1.pdf)). A total of 387 cases (from 400 genotyped) and 5,380 controls remained for analysis in the discovery sample after these steps.

A Hardy--Weinberg equilibrium (HWE) test (in the WTCCC2 control data) identified SNPs with large deviations (p\<0.001) that were excluded from analysis, controlling for possible genotyping errors in the controls. As the cases were genotyped separately, further filtering steps were undertaken to control for possible genotyping error in the cases. See [Appendix 2](http://www.molvis.org/molvis/v18/a115/app-2.pdf) (supplementary methods) for details. All QC steps were performed using [PLINK](http://pngu.mgh.harvard.edu/purcell/plink/) \[[@r22]\], and 681,552 SNPs remained for analysis. A QQ plot is shown in [Appendix 3](http://www.molvis.org/molvis/v18/a115/app-3.pdf).

Statistical analysis
--------------------

We analyzed the data for risk using allelic χ^2^, and further subdivided our cases into NTG and HTG cases which were independently tested against the WTCCC2 controls. The quantitative ocular traits were analyzed by linear regression, with each SNP tested against each of the traits.

GWA studies are prone to detection of false positives; to ensure that the most promising signals were taken through to the replication stage we applied a 'clumping' strategy \[[@r22]\]. Significant SNPs were clumped together as a single association signal if in linkage disequilibrium over a 250 kilobase pair distance. Prioritization for replication was as follows; SNPs with multiple supporting independent clumps in the same region; support from quantitative trait results, as this is not dependent on the WTCCC2 controls; significant SNPs with a p-value ≤10^−6^ with some support in the surrounding region; finally, where clumped results located within a gene, relevant functional data was also taken into consideration.

This multi-pronged approach gave a total of 86 SNPs to test in the replication cohort. All analysis steps were performed using [PLINK](http://pngu.mgh.harvard.edu/purcell/plink/) \[[@r22]\].

Results
=======

GWAS results
------------

There were two SNPs with GWAS significance (p\<1×10^−8^) in the risk analysis, the most significant was on chromosome 6 ([rs11961171](http://www.ncbi.nlm.nih.gov/snp?term=rs11961171), p=8.55±10^−13^) and had 6 SNPs ([rs41463745](http://www.ncbi.nlm.nih.gov/snp?term=rs41463745), [rs4713332](http://www.ncbi.nlm.nih.gov/snp?term=rs4713332), [rs16871186](http://www.ncbi.nlm.nih.gov/snp?term=rs16871186), [rs16871188](http://www.ncbi.nlm.nih.gov/snp?term=rs16871188), [rs4713335](http://www.ncbi.nlm.nih.gov/snp?term=rs4713335), and [rs16871204](http://www.ncbi.nlm.nih.gov/snp?term=rs16871204)) in the clump (p≤0.0002) and four other independent SNPs in the surrounding region ([Figure 1](#f1){ref-type="fig"}). The genes nearest to the signal are neural precursor cell expressed, developmentally down-regulated 9 (*NEDD9*), *LOC100129322*, and transmembrane protein 170B (*TMEM170B*). We chose three independent SNPs to genotype in this region in the replication sample. The second GWAS significant SNP was on chromosome 16 ([rs924463](http://www.ncbi.nlm.nih.gov/snp?term=rs924463)) with no supporting evidence from the surrounding region suggesting a likely false positive. [Figure 2](#f2){ref-type="fig"} shows a Manhattan plot of the risk GWAS.

![A plot of the most significant region in the discovery sample GWAS. This plot shows the region around the most significant result in the discovery sample GWAS. SNPs are plotted as the -log10 of the p-value. The plot was produced using [LocusZoom](http://csg.sph.umich.edu/locuszoom/).](mv-v18-1083-f1){#f1}

![A Manhattan plot of the discovery sample GWAS results. This Manhattan plot shows the results of the discovery sample GWAS for all autosomes. Results are plotted as --log10 of the p-value. The top two results are circled, on chromosome 6 and chromosome 16. No other SNPs reach a stringent genome-wide significance level of 10^-8^. This plot was produced using [Haploview](http://www.broad.mit.edu/mpg/haploview/).](mv-v18-1083-f2){#f2}

Quantitative traits
-------------------

The quantitative ocular traits are summarized in [Table 2](#t2){ref-type="table"}. As expected for POAG cases the IOP was raised, the CDR increased and the CCT reduced compared to controls. The values were similar in the discovery and replication cases.

Replication results
-------------------

For replication 86 SNPs were genotyped in the 294 new cases, 50 controls, as well as the discovery sample allowing data quality checks. The overall concordance rate between the discovery and replication data was \>99%. All SNPs passed the HWE test (p\>0.001 in controls).

SNPs were analyzed for association to the phenotype which led to their inclusion in the replication cohort. Results for the most significant region in the GWAS and all SNPs which showed significant replication are given in [Table 3](#t3){ref-type="table"} and full results are listed in [Appendix 4](http://www.molvis.org/molvis/v18/a115/app-4.pdf). There were 4 results with a p-value \<0.05, none of which pass a multiple testing correction for 86 SNPs. One SNP, located downstream of the gene 'KH domain containing, RNA binding, signal transduction associated 3' (*KHDRBS3*), was significant for average CDR, and in a consistent direction to the discovery data. One SNP, located within the gene 'ubiquitin protein ligase E3 component n-recognin 7' (*UBR7*), was significant for the phenotype CCT and also had an effect in the same direction as the discovery data. Functional information is lacking for *UBR7*. Ocular trait information had also been collected for the 50 Southampton controls, enabling a similar quantitative analysis in controls for these 2 SNPs. Neither was significant perhaps suggesting that their effects are specific to glaucoma cases, although the control sample size is limited. The final 2 significant SNPs (one for HTG and one for NTG) showed association in the opposite direction to the discovery data, indicating false-positive results.

###### Results for the top hit in the POAG GWAS discovery sample, and all nominally significant replication results.

  **Phenotype**                      **SNP**                                                         **Location**     **Nearest gene(s)**   **Frequency of allele 1 in discovery cases, controls,(allele2)/Qtrait mean direction**   **Frequency of allele 1 in replication cases, controls,(allele2)/Qtrait mean direction**   **Discovery p-value**   **Replication p-value**
  ---------------------------------- --------------------------------------------------------------- ---------------- --------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------- -------------------------
  **Most significant GWAS region**                                                                                                                                                                                                                                                                                                                      
  POAG                               [rs11961171](http://www.ncbi.nlm.nih.gov/snp?term=rs11961171)   chr6:11384014    *NEDD9*               A=0.1158, 0.05332 (G)                                                                    A=0.04762, 0.06 (G)                                                                        8.55E-13                0.5974
  POAG                               [rs967473](http://www.ncbi.nlm.nih.gov/snp?term=rs967473)       chr6:11437409    *NEDD9*               A=0.1899, 0.1407 (G)                                                                     A=0.1382, 0.15 (G)                                                                         0.000167                0.7538
  POAG                               [rs9366868](http://www.ncbi.nlm.nih.gov/snp?term=rs9366868)     chr6:11811486    *C6orf105*            A=0.3329, 0.4098 (G)                                                                     A=0.4041, 0.49 (G)                                                                         2.59E-05                0.1074
  **Significant at replication**                                                                                                                                                                                                                                                                                                                        
  avCCT                              [rs17128941](http://www.ncbi.nlm.nih.gov/snp?term=rs17128941)   chr14:92754850   *C14orf130 (UBR7)*    T-\>C increasing CCT                                                                     T-\>C increasing CCT                                                                       5.52E-06                0.02743
  avCDR                              [rs4385494](http://www.ncbi.nlm.nih.gov/snp?term=rs4385494)     chr8:136919236   *KHDRBS3*             T-\>G increasing CDR                                                                     T-\>G increasing CDR                                                                       4.51E-05                0.02937
  HTG                                [rs4237260](http://www.ncbi.nlm.nih.gov/snp?term=rs4237260)     chr9:75931236    *RORB*                C=0.3199, 0.233 (G)                                                                      C=0.206, 0.35 (G)                                                                          4.98E-07                0.001949\*
  NTG                                [rs7785999](http://www.ncbi.nlm.nih.gov/snp?term=rs7785999)     chr7:32427787    *PDE1C*, *LSM5*       A=0.2692, 0.1467 (C)                                                                     A=0.09483, 0.1939 (C)                                                                      9.22E-05                0.02932\*

This table gives the results of the most significant SNPs in the discovery sample and all nominally significant (p\<0.05) results in the replication sample, including allele frequencies for risk analyses and direction of effect for quantitative trait analyses. \*The effect is in opposite directions in the discovery and replication samples.

Previously published POAG genes
-------------------------------

Included in our replication data were 3 SNPs near published POAG risk genes which showed strong evidence for association in our discovery data. SNPs in *SRBD1* and *MTAP* (near *CDKN2B*) both showed strongest evidence for the HTG group, and a SNP in *CDKN2B* which showed strongest evidence in the NTG group. However, these SNPs were not significant in our replication sample ([Appendix 4](http://www.molvis.org/molvis/v18/a115/app-4.pdf)). [Table 4](#t4){ref-type="table"} gives a summary of the evidence for published POAG genes, with *SRBD1, CDKN2B*, and *TMCO1* giving the most convincing evidence in our larger discovery sample. The best of several significant SNPs within *SRBD1* is [rs11884064](http://www.ncbi.nlm.nih.gov/snp?term=rs11884064) (p=6.7×10^−5^), though nearby [rs1657855](http://www.ncbi.nlm.nih.gov/snp?term=rs1657855) is marginally more significant (p=2.69×10^−5^).

###### Evidence for published POAG risk and quantitative trait genes.

  **Gene (region)**   **phenotype**   **Published SNP**                                                                                                                                                                   **Published discovery p-value**      **Reference**       **P-values in our discovery data (where SNP is available)**
  ------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------- -------------------------------------------------------------------------------------------------------------------------------------
  *CAV1/CAV2*         POAG            [rs4236601](http://www.ncbi.nlm.nih.gov/snp?term=rs4236601)                                                                                                                         5.0×10^−10^                          \[[@r9]\]           Not in our data
  *TMCO1*             POAG            [rs7518099](http://www.ncbi.nlm.nih.gov/snp?term=rs7518099)                                                                                                                         4.7×10^−10^                          \[[@r11]\]          8.9×10^−4^
  *SRBD1*             POAG/NTG        [rs3213787](http://www.ncbi.nlm.nih.gov/snp?term=rs3213787)                                                                                                                         2.5×10^−9^                           \[[@r12],[@r26]\]   not in our data. [rs2082876](http://www.ncbi.nlm.nih.gov/snp?term=rs2082876) p=0.0005 POAG, p=4.28×10^-5^ HTG, see results section.
  *CDKN2B*            POAG            [rs10120688](http://www.ncbi.nlm.nih.gov/snp?term=rs10120688)                                                                                                                       1.4×10^−8^                           \[[@r11]\]          1.2×10^-5^\*evidence also in nearby MTAP
  *SIX1*              VCDR/POAG       [rs10483727](http://www.ncbi.nlm.nih.gov/snp?term=rs10483727)                                                                                                                       2.93×10^−10^                         \[[@r15]\]          0.3 CDR/0.076 POAG
  *ELOVL5*            POAG/NTG        [rs735860](http://www.ncbi.nlm.nih.gov/snp?term=rs735860)                                                                                                                           4.14×10^−6^                          \[[@r12]\]          0.6 POAG/0.7 NTG
  *ATOH7*             Disc area       [rs3858145](http://www.ncbi.nlm.nih.gov/snp?term=rs3858145) [rs1900004](http://www.ncbi.nlm.nih.gov/snp?term=rs1900004) [rs690037](http://www.ncbi.nlm.nih.gov/snp?term=rs690037)   6.2×10^−10^ 1.3×10^−10^ 1.5×10^−7^   \[[@r14]\]          We have not tested disc area [rs1900004](http://www.ncbi.nlm.nih.gov/snp?term=rs1900004) p=0.07 for CDR. The others not in our data
  *CDC7/TGFBR3*       Disc area       [rs1192415](http://www.ncbi.nlm.nih.gov/snp?term=rs1192415)                                                                                                                         7.57×10^−17^ (meta p-value)          \[[@r13]\]          not in our data
  *CARD10*            Disc area       [rs9607469](http://www.ncbi.nlm.nih.gov/snp?term=rs9607469)                                                                                                                         2.73×10^−12^ (meta p-value)          \[[@r13]\]          0.79 for CDR
  *ZNF469*            CCT             [rs12447690](http://www.ncbi.nlm.nih.gov/snp?term=rs12447690)                                                                                                                       2.87×10^−8^                          \[[@r16]\]          not in our data
  *COL5A1*            CCT             [rs1536482](http://www.ncbi.nlm.nih.gov/snp?term=rs1536482)                                                                                                                         7.1×10^−8^                           \[[@r17]\]          not in our data
  *AKAP13*            CCT             [rs6496932](http://www.ncbi.nlm.nih.gov/snp?term=rs6496932)                                                                                                                         1.4×10^−8^                           \[[@r17]\]          0.23
  *COL8A2*            CCT             [rs274754](http://www.ncbi.nlm.nih.gov/snp?term=rs274754)                                                                                                                           0.018                                \[[@r27]\]          not in our data
  *AVGR8*             CCT             [rs1034200](http://www.ncbi.nlm.nih.gov/snp?term=rs1034200)                                                                                                                         3.5×10^−9^                           \[[@r17]\]          not in our data

This table lists genes or regions previously published to be associated with POAG or related ocular traits. Published SNPs and p-values are given along with relevant p-values in our discovery sample (where data were available).

We found no association evidence for SNPs within *MYOC*, as expected, since patients with *MYOC* mutations were excluded. Also *MYOC* mutations along with *WDR36* and *OPTN* are rare causes of POAG and thus not expected to be detected by GWAS. We found some very weak evidence in *OPTN* (p=0.02), but none in *WDR36*.

Discussion
==========

We report two SNPs highly significant in our discovery data for the phenotypes CCT and CDR. Both have positive replication data, neither of which withstands a multiple testing correction, but both show direction of effects consistent with the discovery data. The most significant SNP in the POAG risk analysis is located in *NEDD9*. There was strong evidence from surrounding SNPs and *NEDD9* appears an excellent candidate as it has been shown to be increased in trabecular meshwork cells \[[@r23]\], however, none of the 3 SNPs chosen for follow-up in the *NEDD9* region were significant in the replication study. As GWAS studies are prone to type one (false positive) error, we chose to follow-up the SNPs with most evidence, based on a variety of criteria, rather than simply single p-values. We believe our selection criteria enhanced our likelihood of successful replication, but it is possible we may have excluded some real associations.

Several genes of moderate effect have been detected by GWAS, including variants near *CAV1* and *CAV2* \[[@r9]\] and *TMCO1* and *CDKN2B* \[[@r11]\]. We assessed evidence for a list of well replicated published genes in our GWAS ([Table 4](#t4){ref-type="table"}) and found the genes *SRBD1*, *CDKN2B*, and *TMCO1* had the most convincing evidence of association in our data. Interestingly, the best SNP within *SRBD1* is [rs11884064](http://www.ncbi.nlm.nih.gov/snp?term=rs11884064) (p=6.7×10^−5^), though nearby [rs1657855](http://www.ncbi.nlm.nih.gov/snp?term=rs1657855) is marginally more significant (p=2.69×10^−5^) and located upstream of *SRBD1* and nearer the *SIX3* and *SIX2* genes which play roles in eye development.

Few GWAS significant signals have been detected for POAG, even in studies with very large sample size \[[@r9]\]. It seems that the remaining POAG heritability may be accounted for, by rare variants across multiple genes that all contribute to genetic risk and these are not amenable to discovery using genome-wide association methodology. GWAS are aimed at identifying common SNPs with allele frequency of \>5% based on the common variant-common disease hypothesis of disease pathogenesis. These genetic polymorphisms may individually only modestly increase the risk of disease. However, there is increasing evidence that accumulation of rare variants may have a larger impact on complex disease than first thought, and may be responsible for the as yet unaccounted for genetic contribution to some common complex diseases. Recent identification of a rare penetrant variant in AMD as an example \[[@r24]\]. Such variation will be detectable by new methods in next generation sequencing which allows genetic variation to be cataloged for all genic regions or the whole human genome. The genetic variants accounting for the remaining heritability of POAG may be more suited to detection by this type of study. There are also several ocular traits (sub-phenotypes), relevant to POAG diagnosis and disease progression, which have been associated with genetic variation in the population and in the POAG subgroup. There appears to be a complex interplay between genes involved in eye development and maintenance, which are also involved in susceptibility to the common form of glaucoma (POAG) \[[@r25]\].
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POAG cases and WTCCC2 controls are plotted along with HapMap phase3 data. Ethnic groups cluster together and the POAG and WTCCC2 samples cluster together with the HapMap CEU (Utah residents with ancestry from northern and western Europe) and the TSI (Toscans in Italy) samples. The red squares with a white cross labelled 'Remove' are samples that fell away from the main cluster and were removed from analysis. To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v18/a115/app-1.pdf)." This will initiate the download of a compressed (pdf) archive that contains the file.
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